Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06801418 · ClinicalTrials.gov registry record · Phase 1
Bioequivalence Study Between Adagrasib Reference Tablets and High Drug Load Tablets
A Phase 1 study, sponsored by Mirati Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 160
- Enrollment target
NCT06801418 is a Phase 1 study that has completed, run by Mirati Therapeutics. The registered enrollment target is 160 participants.
The verdict
NCT06801418, a Phase 1 study, has completed, sponsored by Mirati Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 160 participants
- Enrollment target
Study Summary
This is a study to evaluate bioequivalence between adagrasib reference tablets and high drug load tablets in healthy adult participants.
Interventions
- DRUG Adagrasib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2025-02-04 |
| Est. Completion | 2025-06-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06801418
The ClinicalTrials.gov registry entry for NCT06801418 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mirati Therapeutics, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Adagrasib is the first listed.
NCT06801418 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06801418 about?
NCT06801418 is a clinical study titled "Bioequivalence Study Between Adagrasib Reference Tablets and High Drug Load Tablets". This is a study to evaluate bioequivalence between adagrasib reference tablets and high drug load tablets in healthy adult participants.
What is the current status of trial NCT06801418?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 160 participants. The study started on 2025-02-04. Estimated completion is 2025-06-19.
What interventions are being tested in trial NCT06801418?
The interventions under investigation include: Adagrasib (DRUG).
Who is sponsoring clinical trial NCT06801418?
This trial is sponsored by Mirati Therapeutics, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.